Atlas Trials

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Clinical trial NCT06276868 · RECRUITING

Trial details

NCT number
NCT06276868
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerHER2-positive Breast Cancer
Start date
2024-01-20
Primary completion
2025-07-01
Enrollment
71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.